- Home
- VACH vs ATYR Comparison
VACH vs ATYR Comparison
Compare VACH & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VACH
- ATYR
- Stock Information
- Founded
- VACH 2023
- ATYR 2005
- Country
- VACH United States
- ATYR United States
- Employees
- VACH N/A
- ATYR N/A
- Industry
- VACH
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VACH
- ATYR Health Care
- Exchange
- VACH NYSE
- ATYR Nasdaq
- Market Cap
- VACH 321.3M
- ATYR 263.9M
- IPO Year
- VACH 2024
- ATYR 2015
- Fundamental
- Price
- VACH $10.21
- ATYR $3.47
- Analyst Decision
- VACH
- ATYR Strong Buy
- Analyst Count
- VACH 0
- ATYR 6
- Target Price
- VACH N/A
- ATYR $18.60
- AVG Volume (30 Days)
- VACH 8.0K
- ATYR 1.4M
- Earning Date
- VACH 01-01-0001
- ATYR 05-01-2025
- Dividend Yield
- VACH N/A
- ATYR N/A
- EPS Growth
- VACH N/A
- ATYR N/A
- EPS
- VACH 0.26
- ATYR N/A
- Revenue
- VACH N/A
- ATYR $235,000.00
- Revenue This Year
- VACH N/A
- ATYR $551.06
- Revenue Next Year
- VACH N/A
- ATYR $2,144.84
- P/E Ratio
- VACH $39.79
- ATYR N/A
- Revenue Growth
- VACH N/A
- ATYR N/A
- 52 Week Low
- VACH $9.95
- ATYR $1.42
- 52 Week High
- VACH $11.20
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- VACH N/A
- ATYR 58.27
- Support Level
- VACH N/A
- ATYR $2.85
- Resistance Level
- VACH N/A
- ATYR $3.15
- Average True Range (ATR)
- VACH 0.00
- ATYR 0.29
- MACD
- VACH 0.00
- ATYR 0.08
- Stochastic Oscillator
- VACH 0.00
- ATYR 86.67
About VACH VOYAGER ACQUISITION CORP.
Voyager Acquisition Corp is a blank check company.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.